Our programs span discovery-stage to late-stage development and cover a range of high-value indications.
We aim to pursue programs we believe could be first-in-class / best-in-class and where there is prior learning in human genetics or precedented human activity for a pathway of interest. We place a premium on learnings from the clinic, whereby a drug has established the relevance of a biological pathway contributing to disease outcome. Our approach is to pursue the best assets in a capital efficient manner and rapidly progress our programs through development, evaluating the unique biological advantage of our product candidates.

Pipeline

pipeline chart header3
SerpinPC
circle button  Hemophilia A, B | Activated Protein C (APC) Inhibitor
LB101
circle button  Solid Tumors | PD-L1xCD47 LockBody®
Undisclosed
circle button  Solid Tumors | PD-L1xCD3 LockBody®
ORX750
circle button  Narcolepsy Type 1 (NT1) and other sleep disorders | Orexin Receptor-2 (OX2R) Agonist
MGX292
circle button  Pulmonary Arterial Hypertension (PAH) | BMP9 Engineered Variant

Centessa has other early-stage programs that are not reflected on this page.

View our Expanded Access Policy for investigational medical products.
READ
Scroll to Top
pipeline chart title phases popup2
SerpinPC
Overview SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. Additional information on the trial can be accessed at www.clinicaltrials.gov (NCT05605678). The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease
Hemophilia A, B
pipeline chart title phases popup2
LB101

Overview
Centessa’s proprietary LockBody technology platform aims to redefine immuno-oncology treatment for patients with cancer. LockBody drug candidates are designed to selectively drive potent effector function activity, such as CD47 or CD3, to the TME while avoiding systemic toxicity. The first LockBody candidate is LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody which has two anti-CD47 domains blocked by two anti-PD-L1 domains, with proprietary human IgG-derived hinges linking the anti-CD47 and anti-PD-L1 domains. The cell-killing mechanism of action, CD47, is designed to be blocked by the PD-L1 tumor targeting domain until the IgG-derived hinges are naturally degraded in the TME, thus unlocking and activating the CD47 effector function activity in the tumor. LB101 is currently in a Phase 1/2a first-in-human trial. Additional information on the LB101 clinical trial can be accessed at www.clinicaltrials.gov. LB101 is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
Up to ~19 million new cases and ~10 million deaths globally, including
~1.9 million and ~600,000 within the United States
Disease
Solid Tumors
pipeline chart title phases popup2
Undisclosed

Overview
We aim to develop novel therapeutics based on our unique LockBody® technology platform, which is designed to selectively drive potent effector function activity, such as CD47 or CD3, while avoiding systemic toxicity. The lead compound is LB101,  a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody in a Phase 1/2a first-in-human trial. We are also developing a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody, which is designed to selectively drive potent CD3 effector function activity while avoiding systemic toxicity.

Reason to Believe in Target
Human Genetics Support

Epidemiology
Up to ~19 million new cases and ~10 million deaths globally, including
~1.9 million and ~600,000 within the United States
Disease
Solid Tumors
pipeline chart title phases popup2
ORX750

Overview
We are developing ORX750, an oral selective orexin receptor 2 (OX2R) agonist designed to leverage unique structural insights and to directly target the underlying pathophysiology of orexin neuron loss in NT1 with potential expansion into other sleep disorders.

Reason to Believe in Target
Precedented Clinical Activity

Epidemiology
Estimated narcolepsy prevalence of over ~150,000 in the United States, of which approx. ~50% have NT1
~3 million prevalence of narcolepsy worldwide
Disease
Narcolepsy Type 1
pipeline chart title phases popup2
MGX292

Overview
We are developing MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in PAH, directly targeting a central underlying disease mechanism (BMP9/BMPR2/ALK1 signaling pathway genetically altered in PAH).

Reason to Believe in Target
Human Genetics Support

Epidemiology
PAH prevalence is 11 to 26 per million individuals, affecting approximately 70,000 patients in North America, Europe and Japan
~1.9 million and ~600,000 within the United States
Disease
Pulmonary Arterial Hypertension (PAH)